Clinical Research Directory

Inclusion criteria: 1\. Histologically confirmed adenocarcinoma of the prostate. 2 The presence of the following studies: TRUS of the prostate gland, pelvis MRI, OSG. 3 Histological evaluation of prostate biopsy with assignment of the Gleason index. 4 Clinical stage T1-3N0M0 (AJCC 7th edition). 5 ECOG performance status 0-1 6 Age limit 18 years. 7 Patient consent to participate in a clinical study. Exclusion criteria: 1. Prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oral cavity) 2. Distatnt metastases. 3. Metastases in the lymph nodes of prostate cancer. 4. Radical prostatectomy or cryodestruction of the prostate gland in history. 5. Radiation of a small pelvis in the anamnesis. Bilateral orchectomy history. 6. Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months, transmural myocardial infarction within the past 6 months, acute bacterial or fungal infection requiring IV antibiotics, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment, hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.